Waldenström Macroglobulinemia: Lymphoplasmacytic Lymphoma

Waldenström Macroglobulinemia (WM) is a specific type of lymphoplasmacytic lymphoma — a B-cell lymphoma in which the cancer cells produce large amounts of a protein called IgM (immunoglobulin M). The excess IgM in the blood causes many of WM's characteristic complications, including hyperviscosity syndrome (thickened blood), peripheral neuropathy, and cold-related symptoms. Unlike most aggressive lymphomas, WM tends to grow slowly and is managed as a chronic condition. Unlike multiple myeloma, which also produces a paraprotein, WM arises from a different cell type and has distinct biology, molecular profile, and treatment approach.

MYD88 L265P is a genetic mutation found in more than 90% of Waldenström Macroglobulinemia cases. MYD88 is a protein that normally signals immune cells to fight infection. The L265P mutation permanently activates this signaling, causing lymphoplasmacytic cells to survive and multiply abnormally. This mutation is clinically important for two reasons: it confirms the WM diagnosis (distinguishing it from other IgM-producing conditions), and it predicts excellent response to BTK inhibitors like ibrutinib and zanubrutinib, which target a key signaling protein downstream of MYD88. Testing for MYD88 L265P is a standard part of WM workup before treatment decisions are made.

Hyperviscosity syndrome occurs when excess IgM protein makes the blood abnormally thick and resistant to flow. This can impair blood circulation throughout the body. Symptoms include blurred or double vision, headaches, dizziness, ringing in the ears, confusion, and in severe cases, stroke-like neurological symptoms or bleeding. It is a medical emergency. Treatment involves plasmapheresis — a procedure that filters the IgM out of the blood plasma — which provides rapid but temporary relief. Definitive control requires effective WM-directed therapy to reduce IgM production.

Both ibrutinib and zanubrutinib are BTK inhibitors — oral medications that block the BTK enzyme that WM cells depend on for survival. Zanubrutinib is more selective for BTK than ibrutinib, which means it has fewer off-target effects. In the ASPEN clinical trial comparing both drugs in WM, zanubrutinib achieved higher rates of complete response and very good partial response than ibrutinib, while also causing less atrial fibrillation (irregular heartbeat). Zanubrutinib is therefore generally preferred, especially in patients with pre-existing heart conditions or who have experienced cardiac side effects on ibrutinib.

No. Many patients with Waldenström Macroglobulinemia are diagnosed without symptoms — often incidentally from blood tests showing an IgM paraprotein or mild anemia — and do not require immediate treatment. This approach is called watch-and-wait. Treatment is initiated only when the patient develops symptoms attributable to WM, such as significant anemia, symptomatic hyperviscosity, significant lymph node or spleen enlargement, severe peripheral neuropathy, or platelet-related bleeding. Many patients remain on observation for years without needing therapy.

CXCR4 is a receptor protein on WM cells that helps them survive and home to the bone marrow. Mutations in the CXCR4 gene are found in about 30% of WM patients. CXCR4 mutations do not prevent BTK inhibitors from working, but they slow the response — patients with CXCR4 mutations typically take longer to achieve their best response to ibrutinib or zanubrutinib and may achieve a shallower depth of response. Researchers are studying venetoclax-based combinations and other strategies specifically for CXCR4-mutant WM.

Currently available standard therapies — including BTK inhibitors and chemoimmunotherapy — are not curative for WM. However, WM is a manageable chronic disease, and most patients can achieve long-term disease control with good quality of life. Deep remissions are increasingly achievable with modern regimens, and a small proportion of patients have achieved sustained undetectable disease. Autologous stem cell transplant offers a potential path to longer remission in selected younger patients. Research into curative strategies including CAR-T cell therapy is ongoing.

Progressive WM may present as rising IgM levels, worsening anemia, new or enlarging lymph nodes, or increasing symptoms. A more concerning development is transformation to Diffuse Large B-Cell Lymphoma (the WM equivalent of Richter transformation), which should be suspected when there is rapidly enlarging lymphadenopathy, significantly elevated LDH, or constitutional symptoms disproportionate to the IgM level. Transformation requires urgent biopsy, restaging, and aggressive lymphoma-directed therapy — distinct from WM management.

Yes. CancerFax works with WM patients and families to facilitate expert second opinions from specialist hematologists experienced in lymphoplasmacytic lymphoma and WM, coordinate review of molecular test results (MYD88, CXCR4), assist with access to zanubrutinib, venetoclax-based regimens, and clinical trial programs including investigational BTK inhibitor strategies. We can also support cross-border care coordination for patients seeking access to WM specialists or therapies available at leading international centers. Contact CancerFax to share your medical reports and begin the process.